10.79 1.27 (13.34%) | 02-19 12:30 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 12.69 ![]() |
1-year : | 14.82 ![]() |
Resists | First : | 10.86 ![]() |
Second : | 12.69 ![]() |
Pivot price | 8.37 ![]() |
|||
Supports | First : | 8.05 ![]() |
Second : | 6.3 |
MAs | MA(5) : | 9.31 ![]() |
MA(20) : | 7.97 ![]() |
MA(100) : | 6.62 ![]() |
MA(250) : | 6.21 ![]() |
|
MACD | MACD : | 0.5 ![]() |
Signal : | 0.3 ![]() |
%K %D | K(14,3) : | 90 ![]() |
D(3) : | 91.8 ![]() |
RSI | RSI(14): 73.9 ![]() |
|||
52-week | High : | 14.6 | Low : | 1.34 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CADL ] has closed It is unclear right now based on current values. 42.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 10.24 - 10.28 | 10.28 - 10.31 |
Low: | 9.18 - 9.23 | 9.23 - 9.27 |
Close: | 9.45 - 9.51 | 9.51 - 9.57 |
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
Wed, 19 Feb 2025
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Tue, 18 Feb 2025
Short Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Decreases By 9.6% - MarketBeat
Mon, 10 Feb 2025
Bank of America Initiates Coverage on Candel Therapeutics (NASDAQ:CADL) - MarketBeat
Fri, 07 Feb 2025
B of A Securities Initiates Coverage of Candel Therapeutics (CADL) with Buy Recommendation - Nasdaq
Mon, 13 Jan 2025
Candel Therapeutics Provides Corporate Update and - GlobeNewswire
Mon, 13 Jan 2025
Candel Therapeutics' Cancer Drug Shows Remarkable 30% Reduction in Prostate Cancer Recurrence - StockTitan
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 44 (M) |
Held by Insiders | 2.59e+007 (%) |
Held by Institutions | 19.9 (%) |
Shares Short | 3,060 (K) |
Shares Short P.Month | 0 (K) |
EPS | -3.455e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -62.1 % |
Return on Equity (ttm) | -1 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | -0.49 |
Sales Per Share | 0 |
EBITDA (p.s.) | -0.78 |
Qtrly Earnings Growth | -1.8 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -29 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 0 |
Price to Cash Flow | 28.27 |
Dividend | 0 |
Forward Dividend | 2.64e+006 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |